Skip to search formSkip to main contentSkip to account menu

HS-106

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Abstract 2703: Overcoming Lapatinib resistance by the fatty acid synthase inhibitor HS-106
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Human epidermal growth factor receptor 2 (HER2… 
2015
2015
Abstract 4457: Novel fatty-acid synthase inhibitor in combination with platinum-based therapy provides increased tumor killing efficacy in luminal breast murine model
While targeted therapies exist for Her2 and Luminal breast cancers there remains a subset of patients that would benefit from… 
2013
2013
A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)